Quince Therapeutics, Inc.
QNCX
$1.22
-$0.04-3.18%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
5/11/2026
-
Finbold Stock News
4/28/2026
-
TipRanks Financial Blog
4/28/2026
-
Nasdaq News: Stocks
4/22/2026
-
TipRanks Financial Blog
4/10/2026
-
TipRanks Financial Blog
4/8/2026
-
Ticker Report
4/2/2026
-
TipRanks Financial Blog
4/2/2026
-
TipRanks Financial Blog
3/31/2026
-
Ticker Report
3/30/2026
-
RTT News - Momentum Stocks
3/30/2026
-
Nasdaq News: Markets
3/30/2026
-
TipRanks Financial Blog
3/30/2026
-
TipRanks Financial Blog
3/30/2026
-
SeekingAlpha.com: All News
3/30/2026
-
Seeking Alpha - Healthcare
3/30/2026
-
Business Wire
3/23/2026
-
TipRanks Financial Blog
3/23/2026
-
TipRanks Financial Blog
3/23/2026
-
The Fly
3/20/2026
-
TipRanks Financial Blog
3/20/2026
-
TipRanks Financial Blog
3/17/2026
-
Ticker Report
2/13/2026
-
Benzinga
2/11/2026
-
Ticker Report
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Friday, April 10, 2026
Period Date
Wednesday, December 31, 2025
Next Filing
Week of May 11 and 15 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
--
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
415 910 5717
Address
611 Gateway Boulevard
South San Francisco, CA 94080
South San Francisco, CA 94080
Country
Year Founded
Business Description
Sector
Quince Therapeutics, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company’s lead asset...
more